Silverback Therapeutics (NASDAQ:SBTX – Get Free Report) and Phathom Pharmaceuticals (NASDAQ:PHAT – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations and earnings.
Institutional & Insider Ownership
74.9% of Silverback Therapeutics shares are held by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 34.4% of Silverback Therapeutics shares are held by insiders. Comparatively, 23.0% of Phathom Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Risk & Volatility
Silverback Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.08, meaning that its stock price is 92% less volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Silverback Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
| Phathom Pharmaceuticals | 0 | 1 | 4 | 1 | 3.00 |
Phathom Pharmaceuticals has a consensus target price of $17.50, indicating a potential upside of 98.19%. Given Phathom Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than Silverback Therapeutics.
Profitability
This table compares Silverback Therapeutics and Phathom Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Silverback Therapeutics | N/A | -29.62% | -28.20% |
| Phathom Pharmaceuticals | -1,292.14% | N/A | -79.57% |
Valuation & Earnings
This table compares Silverback Therapeutics and Phathom Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Silverback Therapeutics | N/A | N/A | -$89.48 million | ($2.42) | -5.99 |
| Phathom Pharmaceuticals | $81.86 million | 7.53 | -$201.59 million | ($5.24) | -1.69 |
Silverback Therapeutics has higher earnings, but lower revenue than Phathom Pharmaceuticals. Silverback Therapeutics is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Phathom Pharmaceuticals beats Silverback Therapeutics on 8 of the 14 factors compared between the two stocks.
About Silverback Therapeutics
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
About Phathom Pharmaceuticals
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
